Info

Curis, Inc. is a drug discovery and development company committed to leveraging signaling pathway drug technologies in seeking to create new medicines, primarily for cancer. The Company’s product development approach consists of generating small molecules to target one or more of the components of such abnormally regulated signaling pathway network to provide therapeutic effect. Product candidates include GDC-0449, small molecule and antibody under the Hedgehog systemic antagonist program; CUDC-101 and others under the targeted cancer development platform, and Hedgehog protein agonist under other research programs.(Source: 10-K)